174 patents
Page 3 of 9
Utility
Complement Inhibitors for Treating Drug-induced Complement-mediated Response
10 Nov 22
Disclosed herein are methods and compositions for reducing or eliminating a complement-mediated response in a patient receiving treatment for a disease or disorder wherein one or more therapeutic agents is administered to the patient along with one or more complement inhibitors.
Yi Wang, Susan Liu-Chen
Filed: 1 Oct 20
Utility
Glycoprotein Manufacturing Process
3 Nov 22
The disclosure provides a method of producing recombinant alkaline phosphatase comprising: (i) inoculating Chinese Hamster Ovary (CHO) cells expressing recombinant alkaline phosphatase in culture medium; (ii) culturing the CHO cells in the culture medium at a temperature of about 37° C.; (iii) adding a combination of nutrient supplements to the cell culture of (ii) at least one day after inoculation, the combination comprising (a) a first animal-derived component-free (ADCF) nutrient supplement comprising one or more amino acids, vitamins, salts, trace elements, poloxamer and glucose, wherein the first ADCF nutrient supplement does not comprise hypoxanthine, thymidine, insulin, L-glutamine, growth factors, peptides, proteins, hydrolysates, phenol red and 2-mercaptoethanol; and (b) a second ADCF nutrient supplement comprising one or more amino acids, wherein the second ADCF nutrient supplement lacks hypoxanthine, thymidine, insulin, L-glutamine, growth factors, peptides, proteins, hydrolysates, phenol red, 2-mercaptoethanol and poloxamer; (iv) decreasing the temperature of the cell culture of (iii) to about 30° C. about 80 hours to 120 hours after the inoculation; and (v) isolating the recombinant alkaline phosphatase from the cell culture of (iv) by at least one chromatography step.
Krishanu MATHUR, Siguang SUI
Filed: 5 Mar 18
Utility
Methods of Measuring Copper Concentration In Biological Samples
20 Oct 22
This disclosure relates to methods of measuring copper concentrations in biological samples.
Mark Ma, Tao Liang, Ryan Pelto
Filed: 11 Sep 20
Utility
Virus Filtration
20 Oct 22
Provided herein are methods of performing viral filtration on a fluid including a recombinant antibody, and the use of these methods in methods of manufacturing or producing the recombinant antibody.
Bianca OLSON, Saravanamoorthy RAJENDRAN, Ryan TEDSTONE
Filed: 20 Apr 22
Utility
Recombinant Glycosylated Eculizumab and Eculizumab Variants
13 Oct 22
The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein having specific glycosylation patterns.
Bruce Andrien, Jeffrey William Hunter, Hunter F. Malanson
Filed: 12 Apr 22
Utility
Dosage and administration of anti-C5 antibodies for treatment of protein-losing enteropathy in patients
4 Oct 22
Provided are methods for clinical treatment of a protein-losing enteropathy, such as lymphangiectasia, using an anti-C5 antibody, or antigen binding fragment thereof, in patients (e.g., pediatric patients).
Orly Eshach Adiv, Camille Bedrosian, Hagit Baris Feldman, Alina Kurolap, Susan Faas McKnight
Filed: 21 May 18
Utility
Use of Anti-fcrn Antibodies In the Treatment of Pemphighus and Pemphigoid Diseases
22 Sep 22
The disclosure relates to methods for treating pemphigus and/or a pemphigoid disease in a subject in need thereof, wherein the methods include administering to a subject in need thereof a therapeutically effective amount of an FcRn inhibitor.
Laurence J. Blumberg, Richard S. Blumberg, John Humphries
Filed: 18 May 20
Utility
Cerdulatinib for treating hematological cancers
20 Sep 22
Disclosed herein are methods and uses of cerdulatinib for treating diseases or conditions, including hematological cancers, and combinations of cerdulatinib for treating such diseases or conditions.
Gregory Coffey, Jiajia Feng, Andrew Steele
Filed: 16 Jul 20
Utility
Anti-C5 antibodies having improved pharmacokinetics
6 Sep 22
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders.
Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
Filed: 23 Jan 20
Utility
Alkaline Phosphatase Polypeptides and Methods of Use Thereof
25 Aug 22
Featured are pharmaceutical compositions that include a soluble alkaline phosphatase for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof.
Walter C. VOEGTLI, Yuhong WU, Jonathan MONTELEONE, Tatyana MEZHEBOVSKY, Eric FALCONE, Yang GUO
Filed: 10 Feb 22
Utility
Bis-choline tetrathiomolybdate for treating Wilson Disease
23 Aug 22
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl Bjartmar, Karl-Heinz Weiss, Michael Schilsky, Frederick Askari, Anna Czlonkowska, Peter Ferenci, Peter Hedera, Aftab Ala
Filed: 19 Aug 20
Utility
Methods for Treatment of Refractory Generalized Myasthenia Gravis with Eculizumab
18 Aug 22
The disclosure provides methods of treating refractory myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5).
Jing Jing Wang, Warren Wasiewski, Fanny O'Brien, Kenji Fujita
Filed: 4 Aug 20
Utility
Inhibitors of protein kinases
16 Aug 22
Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
Filed: 26 Nov 19
Utility
Compositions and Methods for Preparing Factor Xa and Derivatives
11 Aug 22
The present disclosure relates to protein sequences which can be used to generate factor Xa proteins and derivatives thereof.
Genmin Lu
Filed: 5 Aug 20
Utility
Anti-C5A antibodies
9 Aug 22
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
Filed: 12 Sep 19
Utility
Methods for treating craniosynostosis in a patient
2 Aug 22
The disclosure features methods for treating craniosynostosis in a patient (e.g., a patient having hypophosphatasia (HPP) and exhibiting or likely to have increased intracranial pressure (ICP)) by administering a soluble alkaline phosphatase (sALP) to the patient, e.g., in combination with a cranial surgery, e.g., a cranial vault remodeling procedure.
Howard M. Saal, Timothy W. Vogel
Filed: 30 Oct 15
Utility
Methods for treating lysosomal acid lipase deficiency in patients
2 Aug 22
The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency.
Anthony Quinn
Filed: 14 Nov 18
Utility
Methods for Treating Lymphoma
28 Jul 22
Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided.
Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
Filed: 31 Jan 22
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treatment of Atypical Hemolytic Uremic Syndrome (Ahus)
28 Jul 22
Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.
Lori Payton, Christian Mix, Rajendra Pradhan, Andrew Damokosh, Eugene Scott Swenson, Xiang Gao
Filed: 24 Jan 20
Utility
Methods of Treating Vitiligo Using an ANTI-C5 Antibody
21 Jul 22
Provided are methods for clinical treatment of vitiligo using an anti-CS antibody or antigen binding fragment thereof.
Richard Alexander Wells
Filed: 20 May 20